ImetelChat

Sorry you are correct 112 not 120.

First patient dosed however was April of 2021.

I also infer that since the intern results I believe are expected second half of 2026 we are probably getting close to 35%.

I also recall this was expected first half of 2025. We were well into the study at this ...

Joseph Eid has been the CMO since November of 2024 according to his bio on the Geron website. I don’t remember seeing a PR for this change.

I would have however expected a PR for full enrollment for the Impact study. It was over 95% enrolled at the end of July. Any possibility this isn’t filled yet ...

NCT06247787

I think this was discussed last quarter at ASH

Study started 2-4 updated 2-13

The website says EMA has already issued an opinion.

First patient dosed April 2023

50% enrollment achieved December 2023. We are now 14 months past this announcement, low end for BAT survival.

If 35% enrollment was achieved early 2023 mid 2025 would put us at 30 months.

240 patients enrolled December of 2024 80 being on BAT.

With this ...

https://www.biopharmadive.com/news/bristol-myers-luspatercept-commands-mds-asco-rebloyzyl/651284/#:~:text=An%20expanded%20approval%20for%20luspatercept,the%20blood%20disorder%20beta%20thalassemia.

Not sure if this was posted in the past. Small mention of imetelstat and possible combination with ...